地西他滨在造血干细胞移植中的应用

冯一梅; 张曦

doi:10.13201/j.issn.1004-2806.2022.01.014

地西他滨在造血干细胞移植中的应用

冯一梅¹,
张曦^1, ,

- 陆军军医大学新桥医院血液病医学中心，创伤、烧伤与复合伤国家重点实验室，全军血液病中心，重庆市医学重点学科(重庆，400037)
基金项目:
重庆市自然基金面上项目(No：cstc2019jcyjmsxmX0273、cstc2020jcyjmsxmX1086)；国家自然科学基金国际交流合作重点项目(No：82020108004)

详细信息

通讯作者: 张曦，E-mail：zhangxxi@sina.com

中图分类号: R457.7

收稿日期: 2021-01-07

刊出日期: 2022-01-01

Applications of decitabine in hematopoietic stem cell transplantation

FENG Yimei¹,
ZHANG Xi^1, ,

More Information

Corresponding author: ZHANG Xi, E-mail: zhangxxi@sina.com

Received Date: 07 January 2021

Publish Date: 01 January 2022

摘要

- DNA甲基化 /
- 地西他滨 /
- 造血干细胞移植 /
- 移植物抗宿主病
Abstract: DNA methylation is closely related to the occurrence and development of myeloid neoplasms. How should we combine hypomethylating agent decitabine with hematopoietic stem cell transplantation to exert a better synergistic effect? This paper reviewed the usage of decitabine before, during and after hematopoietic stem cell transplantation, and summarized that decitabine can reduce tumor burden, prevent relapse, and play positive effects on graft-versus-host disease and poor graft function. Additionally, the dosage and drug resistance of decitabine were discussed and prospected.
- DNA methylation /
- decitabine /
- hematopoietic stem cell transplantation /
- graft-versus-host disease

HTML全文

参考文献(37)

[1]	Boila LD, Sengupta A. Evolving insights on histone methylome regulation in human acute myeloid leukemia pathogenesis and targeted therapy[J]. Exp Hematol, 2020, 92: 19-31. doi: 10.1016/j.exphem.2020.09.189
[2]	Kubasch AS, Platzbecker U. Beyond the Edge of Hypomethylating Agents: Novel Combination Strategies for Older Adults with Advanced MDS and AML[J]. Cancers(Basel), 2018, 10(6): 158.
[3]	周进, 王婧, 刘辉, 等. 含地西他滨方案桥接异基因造血干细胞移植治疗MDS/AML的效果评估[J]. 中华医学杂志, 2015, 95(12): 920-924. doi: 10.3760/cma.j.issn.0376-2491.2015.12.011
[4]	Sekeres MA, Gerds AT. Established and novel agents for myelodysplastic syndromes[J]. Hematology Am Soc Hematol Educ Program, 2014, 2014(1): 82-89. doi: 10.1182/asheducation-2014.1.82
[5]	郑慧菲, 王婧, 周进, 等. 地西他滨桥接异基因造血干细胞移植治疗骨髓增生异常综合征的疗效分析[J]. 中华血液学杂志, 2015, 36(2): 121-124. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZLL201303013.htm
[6]	Kongtim P, Popat U, Jimenez A, et al. Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for Patients with Chronic Myelomonocytic Leukemia[J]. Biol Blood Marrow Transplant, 2016, 22(1): 47-53. doi: 10.1016/j.bbmt.2015.08.031
[7]	Xu Q, Li Y, Jing Y, et al. Epigenetic modifier gene mutations-positive AML patients with intermediate-risk karyotypes benefit from decitabine with CAG regimen[J]. Int J Cancer, 2020, 146(5): 1457-1467. doi: 10.1002/ijc.32593
[8]	Hui Y, Li Y, Tong X, et al. Reinduction chemotherapy regimen involved decitabine and cladribine improves the prognosis of patients with relapsed or refractory acute myeloid leukemia: A preliminary study[J]. Int J Cancer, 2021 Apr 9. doi: 10.1002/ijc.33595.Onlineaheadofprint.
[9]	de Lima M, Ravandi F, Shahjahan M, et al. Long-term follow-up of a phase Ⅰ study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias[J]. Cancer, 2003, 97(5): 1242-1247. doi: 10.1002/cncr.11184
[10]	Tang XW, Valdez BC, Zhang QQ, et al. Decitabine As Part of a Modified Bu-Cy Conditioning Regimen Significantly Improved the Outcome of High-Risk AML Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation[J]. Blood, 2019, 134(Supplement_1): 3270. doi: 10.1182/blood-2019-123951
[11]	Tang X, Valdez BC, Ma Y, et al. Low-dose decitabine as part of a modified Bu-Cy conditioning regimen improves survival in AML patients with active disease undergoing allogeneic hematopoietic stem cell transplantation[J]. Bone Marrow Transplant, 2021, 56(7): 1674-1682. doi: 10.1038/s41409-021-01238-5
[12]	Cao J, Shi X, Ge L, et al. Which Conditioning Regimen Is More Effective for High-Risk Patients with AML/MDS: Comparing Low-Dose Decitabine Combined with Modified Bucy with Modified Bucy Followed by Allo-HSCT[J]. Haematologica, 2016, 101: 286-286. doi: 10.3324/haematol.2015.133637
[13]	Cao YG, He Y, Zhang SD, et al. Conditioning Regimen of 5-Day Decitabine Administration for Allogeneic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome and Myeloproliferative Neoplasms[J]. Biol Blood Marrow Transplant, 2020, 26(2): 285-291. doi: 10.1016/j.bbmt.2019.09.001
[14]	Wang QY, Li Y, Liang ZY, et al. Decitabine-Containing Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Intermediate-and High-Risk Myelodysplastic Syndrome/Acute Myeloid Leukemia: Potential Decrease in the Incidence of Acute Graft versus Host Disease[J]. Cancer Manag Res, 2019, 11: 10195-10203. doi: 10.2147/CMAR.S229768
[15]	Zhang C, Chen XH, Liu J, et al. Decitabine as a conditioning regimen in haploidentical stem cell transplantation for refractory acute myeloid leukaemia[J]. J Clin Pharm Ther, 2015, 40(3): 336-338. doi: 10.1111/jcpt.12251
[16]	Hu KX, Sun QY, Guo M, et al. A Study of Human Leukocyte Antigen Mismatched Cellular Therapy(Stem Cell Microtransplantation)in High-Risk Myelodysplastic Syndrome or Transformed Acute Myelogenous Leukemia[J]. Stem Cells Transl Med, 2016, 5(4): 524-529. doi: 10.5966/sctm.2015-0196
[17]	Li M, Li C, Geng S, et al. Decitabine With or Without Micro-Transplantation for the Treatment of Intermediate or High-Risk Myelodysplastic Syndrome: A Chinese Single-Center Retrospective Study of 22 Patients[J]. Front Oncol, 2021, 11: 628127. doi: 10.3389/fonc.2021.628127
[18]	Landman S, Cruijsen M, Urbano PCM, et al. DNA Methyltransferase Inhibition Promotes Th1 Polarization in Human CD4(+)CD25(high)FOXP3(+)Regulatory T Cells but Does Not Affect Their Suppressive Capacity[J]. J Immunol Res, 2018, 2018: 4973964.
[19]	Han Y, Tang Y, Chen J, et al. Low-Dose Decitabine for Patients With Thrombocytopenia Following Allogeneic Hematopoietic Stem Cell Transplantation: A Pilot Therapeutic Study[J]. JAMA Oncol, 2015, 1(2): 249-251. doi: 10.1001/jamaoncol.2014.316
[20]	Pusic I, Choi J, Fiala MA, et al. Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome[J]. Biol Blood Marrow Transplant, 2015, 21(10): 1761-1769. doi: 10.1016/j.bbmt.2015.05.026
[21]	Gao L, Zhang Y, Wang S, et al. Effect of rhG-CSF Combined With Decitabine Prophylaxis on Relapse of Patients With High-Risk MRD-Negative AML After HSCT: An Open-Label, Multicenter, Randomized Controlled Trial[J]. J Clin Oncol, 2020, 38(36): 4249-4259. doi: 10.1200/JCO.19.03277
[22]	许国发, 陈婷, 刘焕凤, 等. 小剂量地西他滨治疗异基因造血干细胞移植后早期复发髓系恶性血液病患者的疗效分析[J]. 中华血液学杂志, 2019, 40(8): 681-684.
[23]	王晓果, 陈婷, 刘焕凤, 等. 小剂量地西他滨在异基因造血干细胞移植后早期复发及cGVHD治疗中的作用[J]. 第三军医大学学报, 2016, 38(12): 1362-1365. https://www.cnki.com.cn/Article/CJFDTOTAL-DSDX201612007.htm
[24]	Wang L, Wang LN, Zhou JF, et al. Low-Dose Decitabine Monotherapy Reverses Mixed Chimerism in Adult Patients After Allogeneic Hematopoietic Stem Cell Transplantation With Myeloablative Conditioning Regimen: A Pilot Phase Ⅱ Study[J]. Front Med(Lausanne), 2021, 8: 627946.
[25]	Kalin B, van Norden Y, van Gelder M, et al. Panobinostat and decitabine prior to donor lymphocyte infusion in allogeneic stem cell transplantation[J]. Blood Adv, 2020, 4(18): 4430-4437. doi: 10.1182/bloodadvances.2020002074
[26]	Schuler E, Wagner-Drouet EM, Ajib S, et al. Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group[J]. Ann Hematol, 2021, 100(4): 959-968. doi: 10.1007/s00277-020-04321-x
[27]	Roman-Gomez J, Jimenez-Velasco A, Castillejo JA, et al. Promoter hypermethylation of cancer-related genes: a strong independent prognostic factor in acute lymphoblastic leukemia[J]. Blood, 2004, 104(8): 2492-2498. doi: 10.1182/blood-2004-03-0954
[28]	Takeuchi S, Matsushita M, Zimmermann M, et al. Clinical significance of aberrant DNA methylation in childhood acute lymphoblastic leukemia[J]. Leuk Res, 2011, 35(10): 1345-1349. doi: 10.1016/j.leukres.2011.04.015
[29]	Schafer E, Irizarry R, Negi S, et al. Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia: biology and therapeutic targeting[J]. Blood, 2010, 115(23): 4798-4809. doi: 10.1182/blood-2009-09-243634
[30]	Bhatla T, Wang J, Morrison DJ, et al. Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia[J]. Blood, 2012, 119(22): 5201-5210. doi: 10.1182/blood-2012-01-401687
[31]	Feng Y, Li X, Cassady K, et al. TET2 Function in Hematopoietic Malignancies, Immune Regulation, and DNA Repair[J]. Front Oncol, 2019, 9: 210. doi: 10.3389/fonc.2019.00210
[32]	龚婧晔, 肖志坚. 骨髓增生异常综合征患者感染危险因素及预防[J]. 临床血液学杂志, 2021, 34(1): 65-70. https://www.cnki.com.cn/Article/CJFDTOTAL-LCXZ202101016.htm
[33]	Sohn SK, Moon JH, Lee IH, et al. No benefit of hypomethylating agents compared to supportive care for higher risk myelodysplastic syndrome[J]. Korean J Intern Med, 2018, 33(6): 1194-1202. doi: 10.3904/kjim.2016.426
[34]	D'Angelo CR, Hall A, Woo KM, et al. Decitabine induction with myeloablative conditioning and allogeneic hematopoietic stem cell transplantation in high-risk patients with myeloid malignancies is associated with a high rate of infectious complications[J]. Leuk Res, 2020, 96: 106419. doi: 10.1016/j.leukres.2020.106419
[35]	Shargian-Alon L, Gurion R, Raanani P, et al. Hypomethylating Agents-associated Infections-Systematic Review and Meta-analysis of Randomized Controlled Trials[J]. Clin Lymphoma Myeloma Leuk, 2018, 18(9): 603-610. e1. doi: 10.1016/j.clml.2018.05.017
[36]	杨倩, 聂淑敏, 黄俊霞, 等. 地西他滨为主方案治疗中高危骨髓增生异常综合征患者的病态造血变化及预后价值分析[J]. 临床血液学杂志, 2020, 33(3): 191-194. https://www.cnki.com.cn/Article/CJFDTOTAL-LCXZ202003009.htm
[37]	Dear AE. Epigenetic Modulators and the New Immunotherapies[J]. N Engl J Med, 2016, 374(7): 684-686. doi: 10.1056/NEJMcibr1514673